questionsmedicales.fr
Lipides
Lipides membranaires
Sphingolipides
Glycosphingolipides
Glycosphingolipides acides
Gangliosides
Gangliosides : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Maladies métaboliques
Tests génétiques
Symptômes neurologiques
Dysfonction musculaire
Imagerie par résonance magnétique
Anomalies cérébrales
Antécédents familiaux
Maladies génétiques
Symptômes
5
Troubles neurologiques
Retard de développement
Système nerveux
Fonctionnement neuronal
Lésions cutanées
Anomalies pigmentaires
Troubles cognitifs
Accumulation de gangliosides
Douleurs musculaires
Atteinte musculaire
Prévention
5
Prévention
Dépistage génétique
Conseil génétique
Risque familial
Vaccinations
Prévention des maladies
Alimentation équilibrée
Santé générale
Tests de dépistage
Mutations génétiques
Traitements
5
Thérapie enzymatique
Gestion des symptômes
Thérapie génique
Recherche médicale
Essais cliniques
Traitements expérimentaux
Soutien nutritionnel
Qualité de vie
Complications
5
Complications neurologiques
Infections
Handicaps
Dysfonctionnement
Maladies auto-immunes
Maladies métaboliques
Complications
Gestion des symptômes
Gestion des complications
Approche multidisciplinaire
Facteurs de risque
5
Antécédents familiaux
Mutations génétiques
Origines ethniques
Risque génétique
Facteurs environnementaux
Risque
Antécédents médicaux
Maladies métaboliques
Mutations héréditaires
Transmission génétique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gangliosides : Questions médicales les plus fréquentes",
"headline": "Gangliosides : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gangliosides : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-06",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gangliosides"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Glycosphingolipides acides",
"url": "https://questionsmedicales.fr/mesh/D020384",
"about": {
"@type": "MedicalCondition",
"name": "Glycosphingolipides acides",
"code": {
"@type": "MedicalCode",
"code": "D020384",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Ganglioside GM1",
"alternateName": "G(M1) Ganglioside",
"url": "https://questionsmedicales.fr/mesh/D005677",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioside GM1",
"code": {
"@type": "MedicalCode",
"code": "D005677",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025.475.390"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ganglioside GM2",
"alternateName": "G(M2) Ganglioside",
"url": "https://questionsmedicales.fr/mesh/D005678",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioside GM2",
"code": {
"@type": "MedicalCode",
"code": "D005678",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025.475.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ganglioside GM3",
"alternateName": "G(M3) Ganglioside",
"url": "https://questionsmedicales.fr/mesh/D005679",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioside GM3",
"code": {
"@type": "MedicalCode",
"code": "D005679",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025.475.510"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Gangliosides",
"alternateName": "Gangliosides",
"code": {
"@type": "MedicalCode",
"code": "D005732",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sandro Sonnino",
"url": "https://questionsmedicales.fr/author/Sandro%20Sonnino",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy. sandro.sonnino@unimi.it."
}
},
{
"@type": "Person",
"name": "Laura Mauri",
"url": "https://questionsmedicales.fr/author/Laura%20Mauri",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy."
}
},
{
"@type": "Person",
"name": "Jin-Ichi Inokuchi",
"url": "https://questionsmedicales.fr/author/Jin-Ichi%20Inokuchi",
"affiliation": {
"@type": "Organization",
"name": "Division of Glycopathology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, Japan."
}
},
{
"@type": "Person",
"name": "Ronald L Schnaar",
"url": "https://questionsmedicales.fr/author/Ronald%20L%20Schnaar",
"affiliation": {
"@type": "Organization",
"name": "Departments of Pharmacology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States."
}
},
{
"@type": "Person",
"name": "Massimo Aureli",
"url": "https://questionsmedicales.fr/author/Massimo%20Aureli",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Operations research and analytics to combat human trafficking: A systematic review of academic literature.",
"datePublished": "2022-08-29",
"url": "https://questionsmedicales.fr/article/36037198",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0273708"
}
},
{
"@type": "ScholarlyArticle",
"name": "Analysis of operations research methods for decision problems in the industrial symbiosis: a literature review.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36006535",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11356-022-22507-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Capacity building in operational research on obstetric fistula: Experience in the Democratic Republic of Congo, 2017-2021.",
"datePublished": "2022-08-12",
"url": "https://questionsmedicales.fr/article/35900176",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijgo.14377"
}
},
{
"@type": "ScholarlyArticle",
"name": "Defining operational research priorities to improve malaria control and elimination in sub-Saharan Africa: results from a country-driven research prioritization setting process.",
"datePublished": "2023-07-30",
"url": "https://questionsmedicales.fr/article/37517990",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12936-023-04654-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Down referral and assessing comprehensive diabetes care in primary care settings: An operational research from India.",
"datePublished": "2022-12-18",
"url": "https://questionsmedicales.fr/article/36563492",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.dsx.2022.102694"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Lipides",
"item": "https://questionsmedicales.fr/mesh/D008055"
},
{
"@type": "ListItem",
"position": 3,
"name": "Lipides membranaires",
"item": "https://questionsmedicales.fr/mesh/D008563"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sphingolipides",
"item": "https://questionsmedicales.fr/mesh/D013107"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosphingolipides",
"item": "https://questionsmedicales.fr/mesh/D006028"
},
{
"@type": "ListItem",
"position": 6,
"name": "Glycosphingolipides acides",
"item": "https://questionsmedicales.fr/mesh/D020384"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gangliosides",
"item": "https://questionsmedicales.fr/mesh/D005732"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gangliosides - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gangliosides",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gangliosides",
"description": "Comment diagnostiquer une maladie liée aux gangliosides ?\nQuels tests sont utilisés pour détecter les gangliosides ?\nLes symptômes peuvent-ils indiquer un problème de gangliosides ?\nQuelle imagerie est utile pour évaluer les gangliosides ?\nLes antécédents familiaux sont-ils importants pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Operations+Research#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gangliosides",
"description": "Quels sont les symptômes courants des gangliosidoses ?\nLes gangliosides affectent-ils le système nerveux ?\nPeut-on observer des symptômes cutanés ?\nLes troubles cognitifs sont-ils liés aux gangliosides ?\nLes douleurs musculaires sont-elles un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Operations+Research#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gangliosides",
"description": "Peut-on prévenir les gangliosidoses ?\nLe conseil génétique est-il recommandé ?\nLes vaccinations peuvent-elles aider ?\nL'alimentation peut-elle jouer un rôle préventif ?\nLes tests de dépistage sont-ils utiles ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Operations+Research#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gangliosides",
"description": "Quels traitements existent pour les gangliosidoses ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider ?\nY a-t-il des traitements expérimentaux disponibles ?\nLe soutien nutritionnel est-il important ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Operations+Research#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gangliosides",
"description": "Quelles complications peuvent survenir ?\nLes gangliosidoses peuvent-elles entraîner des handicaps ?\nY a-t-il un risque accru de maladies associées ?\nLes complications sont-elles réversibles ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Operations+Research#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gangliosides",
"description": "Quels sont les facteurs de risque des gangliosidoses ?\nLes origines ethniques influencent-elles le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes antécédents médicaux familiaux sont-ils significatifs ?\nLes mutations génétiques sont-elles héréditaires ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Operations+Research#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une maladie liée aux gangliosides ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques, des analyses biochimiques et des biopsies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les gangliosides ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses de tissus peuvent être effectués pour détecter les gangliosides."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils indiquer un problème de gangliosides ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques ou musculaires peuvent suggérer une dysfonction des gangliosides."
}
},
{
"@type": "Question",
"name": "Quelle imagerie est utile pour évaluer les gangliosides ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM peut aider à visualiser les anomalies cérébrales associées aux gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils importants pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents familiaux de maladies génétiques peuvent orienter le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des gangliosidoses ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles neurologiques, des retards de développement et des problèmes moteurs."
}
},
{
"@type": "Question",
"name": "Les gangliosides affectent-ils le système nerveux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les gangliosides sont essentiels pour le fonctionnement normal du système nerveux."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines gangliosidoses peuvent provoquer des lésions cutanées ou des anomalies pigmentaires."
}
},
{
"@type": "Question",
"name": "Les troubles cognitifs sont-ils liés aux gangliosides ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs peuvent survenir en raison de l'accumulation de gangliosides dans le cerveau."
}
},
{
"@type": "Question",
"name": "Les douleurs musculaires sont-elles un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent être présentes en raison de l'atteinte des gangliosides."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les gangliosidoses ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est limitée, mais le dépistage génétique peut aider à identifier les porteurs."
}
},
{
"@type": "Question",
"name": "Le conseil génétique est-il recommandé ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le conseil génétique est conseillé pour les familles à risque de gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas les gangliosidoses, mais protègent contre d'autres maladies."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle jouer un rôle préventif ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé générale, mais ne prévient pas les gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils utiles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests de dépistage peuvent identifier les porteurs de mutations génétiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les gangliosidoses ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la thérapie enzymatique, la gestion des symptômes et le soutien psychologique."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en cours d'étude pour certaines gangliosidoses, mais n'est pas encore standard."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent soulager les symptômes, mais ne traitent pas la cause sous-jacente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques sont en cours pour de nouveaux traitements des gangliosidoses."
}
},
{
"@type": "Question",
"name": "Le soutien nutritionnel est-il important ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un soutien nutritionnel peut aider à améliorer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques graves, des infections et des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Les gangliosidoses peuvent-elles entraîner des handicaps ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines gangliosidoses peuvent entraîner des handicaps physiques ou mentaux permanents."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent avoir un risque accru de maladies auto-immunes ou métaboliques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des complications des gangliosidoses ne sont pas réversibles et nécessitent une gestion."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire incluant médecins et thérapeutes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque des gangliosidoses ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des origines ethniques spécifiques."
}
},
{
"@type": "Question",
"name": "Les origines ethniques influencent-elles le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines populations, comme les Ashkénazes, ont un risque plus élevé de gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, les facteurs environnementaux ne sont pas clairement établis comme des risques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux familiaux sont-ils significatifs ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents médicaux de maladies métaboliques augmentent le risque de gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques sont-elles héréditaires ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations génétiques responsables des gangliosidoses sont souvent héréditaires."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 31/03/2025
Contenu vérifié selon les dernières recommandations médicales
6 publications dans cette catégorie
Affiliations :
Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy. sandro.sonnino@unimi.it.
5 publications dans cette catégorie
Affiliations :
Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy.
Publications dans "Gangliosides" :
5 publications dans cette catégorie
Affiliations :
Division of Glycopathology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Core for Medicine and Science Collaborative Research and Education (MS-CORE), Project Research Center for Fundamental Sciences, Osaka University, Japan.
Publications dans "Gangliosides" :
4 publications dans cette catégorie
Affiliations :
Departments of Pharmacology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Publications dans "Gangliosides" :
4 publications dans cette catégorie
Affiliations :
Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy.
Publications dans "Gangliosides" :
4 publications dans cette catégorie
Affiliations :
Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy.
Publications dans "Gangliosides" :
4 publications dans cette catégorie
Affiliations :
Division of Glycopathology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Publications dans "Gangliosides" :
3 publications dans cette catégorie
Affiliations :
Research team for Geriatric Medicine (Vascular Medicine), Tokyo Metropolitan Institute of Gerontology, Sakaecho 35-2, Itabashi-ku, Tokyo 173-0015, Japan.
Publications dans "Gangliosides" :
3 publications dans cette catégorie
Affiliations :
Research team for Geriatric Medicine (Vascular Medicine), Tokyo Metropolitan Institute of Gerontology, Sakaecho 35-2, Itabashi-ku, Tokyo 173-0015, Japan.
Publications dans "Gangliosides" :
3 publications dans cette catégorie
Affiliations :
J. Heyrovský Institute of Physical Chemistry of the Czech Academy of Sciences, Prague 8, Czech Republic.
Publications dans "Gangliosides" :
3 publications dans cette catégorie
Affiliations :
J. Heyrovský Institute of Physical Chemistry of the Czech Academy of Sciences, Prague 8, Czech Republic.
Publications dans "Gangliosides" :
3 publications dans cette catégorie
Affiliations :
J. Heyrovský Institute of Physical Chemistry of the Czech Academy of Sciences, Prague 8, Czech Republic.
Publications dans "Gangliosides" :
3 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.
Publications dans "Gangliosides" :
3 publications dans cette catégorie
Affiliations :
Department of Medical Biotechnology and Translational Medicine, University of Milano, Via Fratelli Cervi 93, Segrate, Milano, 20054, Italy. elena.chiricozzi@unimi.it.
Publications dans "Gangliosides" :
3 publications dans cette catégorie
Affiliations :
Department of Medical Biotechnology and Translational Medicine, University of Milano, Via Fratelli Cervi 93, Segrate, Milano, 20054, Italy.
Publications dans "Gangliosides" :
2 publications dans cette catégorie
Affiliations :
Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China.
Publications dans "Gangliosides" :
2 publications dans cette catégorie
Affiliations :
Department of Social Medicine and Health Education, School of Public Health, Peking University, Beijing, China.
Publications dans "Gangliosides" :
2 publications dans cette catégorie
Affiliations :
Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China.
Publications dans "Gangliosides" :
2 publications dans cette catégorie
Affiliations :
Department of Obstetrics and Gynaecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Publications dans "Gangliosides" :
2 publications dans cette catégorie
Affiliations :
Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China. Email: yumeiz2020@126.com.
Publications dans "Gangliosides" :
Human trafficking is a widespread and compound social, economic, and human rights issue occurring in every region of the world. While there have been an increasing number of anti-human trafficking stu...
Industrial symbiosis (IS) is an approach that aims to use resources efficiently by cooperating between independent enterprises in raw materials, energy, and similar sectors. As a result of cooperation...
To implement a Flexible Operational Research Training (FORT) course within the Fistula Care Plus Project, Democratic Republic of Congo, from 2017 to 2021....
A descriptive study using design and implementation (process and outcome) data. Two to four members of medical teams from three supported sites were selected for the training based on their research i...
Two courses (13-14 months each) involving nine facilitators and 17 participants overall were conducted between 2017 and 2021. Most participants in both courses were medical doctors (67% and 71%, respe...
The FORT model proved feasible, efficient, and successful. However, scaling up will require more adaptation efforts from programs and participating sites....
In order to reignite gains and accelerate progress toward improved malaria control and elimination, policy, strategy, and operational decisions should be derived from high-quality evidence. The U.S. P...
Five key stakeholder groups were engaged in the process: national malaria programmes (NMPs), research institutions in SSA, World Health Organization (WHO) representatives in SSA, international funding...
Altogether, 47 interviews were conducted with 82 individuals, and through the online survey, input was provided by 46 global technical partners. A total of 33 emergent OR and PE topics were identified...
The prioritized research list is intended to serve as a key resource for informing OR and PE investments, thereby ensuring future investments focus on generating the evidence needed to strengthen nati...
In this study, we aimed to refer eligible (patients with stable blood sugar and without any history of cardiovascular events or proliferative retinopathy) and willing persons with diabetes (PwDs) to p...
This before-after interventional study was conducted among PwDs aged ≥18 years at a tertiary care hospital in South India. Care indicators (regularity to the clinic, waiting time, and blood sugar cont...
Of 204 PwDs referred to PHCs. Among them, 88% (n = 180) registered at PHCs for care and 46% (n = 94, 95% CI 39.1-53.2%) were lost to follow-ups at PHCs. The main reason for loss to follow-ups was the ...
Primary care was better than tertiary care in terms of PwD's regularity of clinic visits and waiting time for care....
Inefficient management of resources and waiting lists for high-risk ophthalmology patients can contribute to sight loss. The aim was to develop a decision support tool which determines an optimal pati...
The Ministry of Health and Family Welfare has introduced the "National Patient Safety Implementation Framework" to ensure the patient safety at different levels of healthcare delivery system. However,...
This was a facility-level survey conducted by research assistants who visited 18 public health facilities across 6 districts of Tamil Nadu, India, for the purpose of documenting the presence of struct...
Only one facility (subdistrict hospital) belonged to the high-performing category with a score of 79.5 on the implementation of patient safety practices. About 11 facilities (4 medical colleges and 7 ...
The study concludes that based on the current situation of patient safety practices in public health facilities, it will be difficult to perform full-fledged implementation of patient safety framework...
Family planning averts unintended pregnancies, unsafe abortions, and maternal deaths, while improving child health and socio-economic progress, but an estimated 218 million women and girls in low- and...
To determine the impact of CoH on promoting healthy timing and spacing of pregnancies and family planning (HTSP/FP) by mothers of children under two years old in select parts of Kenya and Ghana. To al...
A mixed methods operations research comprising quantitative (quasi-experimental design with surveys of 4,372 mothers of children under two years old) and qualitative arms (in-depth interviews of 17 fa...
Taking both countries together, male sterilization, female condom, and LAM were the only FP methods that did not show increases from baseline to endline. Methods with the highest knowledge increases b...
The HTSP/FP model has potential for positive health and social transformation that is built on the trust of faith leaders. Ghana and Kenya provide great examples of possible scenarios in order to help...
Kilifi County, Kenya, has a modern contraceptive prevalence of 44%, compared to the national prevalence of 61%. In 2018, the Government of Kenya and Population Services Kenya implemented a pilot proje...
The Riziki Demonstration Project task shifted contraceptive injectable and implant provision to community health extension workers (CHEWs) and supported community engagement led by community health vo...
We obtained monthly contraceptive service provision data from DHIS2 for intervention and comparison facilities from June 2018 to July 2020. Controlled interrupted time series analyses were used to ass...
We found positive difference-in-differences effects for levels of provision for implant (adj. β = 7.4 per month, per facility, 95% confidence interval [CI]: 2.8-12.0) and all methods combined (adj. β ...
Findings demonstrate the potential for task sharing combined with community engagement efforts to improve contraceptive awareness, knowledge and supply. Community engagement should include men, tradit...
This report is based on the 2021 annual meeting of the Asia-Pacific Malaria Elimination Network Surveillance and Response Working Group held online on November 1-3, 2021. In light of the 2030 regional...
An online annual meeting was hosted from 1 to 3 November 2021, to reflect on research needed to support malaria elimination in the region, challenges with malaria data quality and integration, current...
127 participants from 13 country partners and 44 partner institutions attended the meeting, identifying strategies to address malaria transmission amongst mobile and migrant populations as the top res...
The 2021 SRWG annual meeting provided an opportunity for regional stakeholders, both NMCPs and APMEN partner institutions, to highlight remaining challenges and barriers and identify research prioriti...